# Evaluation of the Safety and Immunogenicity of SII Vaccine Constructs Based on the SARS-CoV-2 (COVID-19) Variant in Adults

> **NCT05029856** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Novavax**

## Conditions studied

- Covid19

## Interventions

- **BIOLOGICAL:** SII B.1.351
- **BIOLOGICAL:** SII B.1.351
- **BIOLOGICAL:** SII Bivalent
- **BIOLOGICAL:** SII Bivalent
- **BIOLOGICAL:** SII B.1.617.2

## Key facts

- **NCT ID:** NCT05029856
- **Lead sponsor:** Novavax
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-02-04
- **Primary completion:** 2022-08
- **Final completion:** 2022-08
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study never started
- **Last updated:** 2022-05-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05029856

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05029856, "Evaluation of the Safety and Immunogenicity of SII Vaccine Constructs Based on the SARS-CoV-2 (COVID-19) Variant in Adults". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05029856. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*